Real-world study of hepatitis C treatment with direct-acting antivirals in patients with drug abuse and opioid agonist therapy

References

• Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–176.
   PubMed Web of Science ®Google Scholar
• Midgard H, Weir A, Palmateer N, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol. 2016;65:S33–S45.
   PubMed Web of Science ®Google Scholar
• Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57:S80–S89.
   PubMed Web of Science ®Google Scholar
• Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.
   PubMed Web of Science ®Google Scholar
• Macias J, Palacios RB, Claro E, et al. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver Int. 2008;28:781–786.
   PubMed Web of Science ®Google Scholar
• Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–456.
   PubMed Web of Science ®Google Scholar
• Khan KN, Yatsuhashi H. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients. Alcohol Alcohol. 2000;35:286–295.
   PubMed Web of Science ®Google Scholar
• Metts J, Carmichael L, Kokor W, et al. Hepatitis C: prevalence, transmission, screening, and prevention. FP Essent. 2014;427:11–17.
   PubMedGoogle Scholar
• AASLD. HCV guidelines. Available from: https://www.hcvguidelines.org/.
   Google Scholar
• Dore GJ, Altice F, Litwin AH, et al. Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165:625–634.
   PubMed Web of Science ®Google Scholar
• Grebely J, Mauss S, Brown A, et al. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials. Clin Infect Dis. 2016;63:1405–1411.
   PubMed Web of Science ®Google Scholar
• Lalezari J, Sullivan JG, Varunok P, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol. 2015;63:364–369.
   PubMed Web of Science ®Google Scholar
• Grebely J, Dore GJ, Zeuzem S, et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clin Infect Dis. 2016;63:1479–1481.
   PubMed Web of Science ®Google Scholar
• Norton BL, Fleming J, Bacchuber MA, et al. High HCV cure rates for drug users treated with DAAs at an urban primary care clinic. Int J Drug Policy. 2016;59:65.
   Google Scholar
• Conway B, et al. Efficacy of all-oral HCV therapy in people who inject drugs (PWID). In: Hepatology. Hoboken (NJ): Wiley-Blackwell; 2016.
   Google Scholar
• Morris L, Smirnov A, Kvassay A, et al. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: findings from the Queensland Injectors’ Health Network. Int J Drug Policy. 2017;47:216–220.
   PubMed Web of Science ®Google Scholar
• Read P, Lothian R, Chronister K, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy. 2017;47:209–215.
   PubMed Web of Science ®Google Scholar
• Bouscaillou J, Kikvidze T, Butsashvili M, et al. Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle income countries (MIC): the results of a prospective cohort study in Tbilisi, Georgia. J Hepatol. 2017;66:S409.
   Web of Science ®Google Scholar
• Sulkowski M, Ward KM, Falade-Nwulia O, et al. Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfected persons who inject drugs: the CHAMPS Study. J Hepatol. 2017;66:S719.
   Google Scholar
• Mason K, Dodd Z, Guyton M, et al. Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. Int J Drug Policy. 2017;47:202–208.
   PubMed Web of Science ®Google Scholar
• Asher AK, Portillo CJ, Cooper BA, et al. Clinicians' views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs. Subst Use Misuse. 2016;51:1218–1223.
   PubMed Web of Science ®Google Scholar
• Lanini S, Easterbrook PJ, Zumla A, et al. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016;22:833–838.
   PubMed Web of Science ®Google Scholar
• Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3:153–161.
   PubMed Web of Science ®Google Scholar
• Hajarizadeh B, Cunningham EB, Reid H, et al. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:754–767.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Reddy KR, Di Bisceglie, et al. ABT-450/r/ombitasvir plus dasabuvir with or without ribavirin in HCV genotype 1-infected patients with history of depression or bipolar disorder: pooled analysis of efficacy and safety in phase 3 trials. In: 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases. Boston, Massachusetts, 7–11 November 2014.
   Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–1603.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection. Ann Intern Med. 2015;163:1–13.
   PubMed Web of Science ®Google Scholar
• Grebley J, Puoti M, Wedemeyer H, et al. Safety and efficacy of ombitasvir, paritaprevir/ritonavir and dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials. J Hepatol. 2017;66:S514.
   PubMed Web of Science ®Google Scholar
• Grebely J, Gregory J, Stefan Z, et al. SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy. J Hepatol. 2017;66:S513–S514.
   Web of Science ®Google Scholar
• Grebely J, Alavi M, Micallef M, et al. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction. 2016;111:311–319.
   PubMed Web of Science ®Google Scholar
• Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Res. 2014;104:62–72.
   PubMed Web of Science ®Google Scholar
• Grebely J, Hajarizadeh B, Dore GJ. Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol. 2017;14:641.
   PubMed Web of Science ®Google Scholar
• Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101:2254.
   PubMed Web of Science ®Google Scholar
• Ho SB, Bräu N, Cheung R, et al. Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse. Clin Gastroenterol Hepatol. 2015;13:2005–2014.e3.
   PubMed Web of Science ®Google Scholar
• Trooskin SB, Poceta J, Towey CM, et al. Results from a geographically focused, community-based HCV screening, linkage-to-care and patient navigation program. J Gen Intern Med. 2015;30:950–957.
   PubMed Web of Science ®Google Scholar
• Falade‐Nwulia O, Mehta SH, Lasola J, et al. Public health clinic‐based hepatitis C testing and linkage to care in Baltimore. J Viral Hepatitis. 2016;23:366–374.
   PubMed Web of Science ®Google Scholar
• Aspinall EJ, Weir A, Sacks-Davis R, et al. Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study. Int J Drug Policy. 2014;25:179–182.
   PubMed Web of Science ®Google Scholar
• Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale‐up in the age of direct‐acting antivirals. Hepatology. 2013;58:1598–1609.
   PubMed Web of Science ®Google Scholar